Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
ACADEMIA
After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
AnGes’ HGF gene therapy Collategene (beperminogene perplasmid) is expected to be launched in Japan by the end of the year after it skipped reimbursement listing in May, the founder of the Osaka-based biotech said on July 20. “I think it…
To read the full story
Related Article
ACADEMIA
- 80% of Diabetes Patients on Antihypertensives Use ACE Inhibitors/ARBs: MHLW Study
August 19, 2019
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
- NCC Hospital Crafting Scheme to Offer Off-Label Meds after Genomic Profiling
July 23, 2019
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
- Japanese Data More Positive for Keytruda’s Frontline Use in Gastric Cancer
July 22, 2019
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…